FDA Biologics (BLA & Biosimilars)Original article
Public Meeting on the Reauthorization of the Biosimilar User Fee Act (BsUFA) - 10/26/2026
RegulatoryNeutral
AI Analysis
Summary
The FDA announced a public meeting on October 26, 2026 regarding the reauthorization of the Biosimilar User Fee Act (BsUFA). No company-specific or drug-specific information is provided.
Outcome Details
FDA public meeting on reauthorization of the Biosimilar User Fee Act (BsUFA); no outcome or decision announced.
Importance:4/10
Sentiment:
0.00
BsUFAbiosimilarsuser feesFDAregulatorypublic meetingreauthorization
Read the original article
Published by FDA Biologics (BLA & Biosimilars) on October 19, 2026 6:24 PM